Iqvia Partners with Duke Clinical Research Institute to Enhance Obesity Research
Iqvia and the Duke Clinical Research Institute announced their new collaboration to enhance the conduct of clinical research in obesity and related cardiometabolic trials. "By combining Iqvia's operational excellence and global reach with DCRI's academic rigor, we are setting a new standard for prospective collaboration between life science service companies and academic research organizations to accelerate clinical trial planning and delivery in obesity and related therapeutic areas," said Jeffrey Spaeder, chief medical and scientific officer, Iqvia. "Uniting our combined clinical strength and complementary capabilities enables us to maximize trial efficiency, accelerate timelines and ultimately bring impactful therapies to patients faster."
